Search Results - "Witek, Gabriela M."

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma by Berko, Esther R., Witek, Gabriela M., Matkar, Smita, Petrova, Zaritza O., Wu, Megan A., Smith, Courtney M., Daniels, Alex, Kalna, Joshua, Kennedy, Annie, Gostuski, Ivan, Casey, Colleen, Krytska, Kateryna, Gerelus, Mark, Pavlick, Dean, Ghazarian, Susan, Park, Julie R., Marachelian, Araz, Maris, John M., Goldsmith, Kelly C., Radhakrishnan, Ravi, Lemmon, Mark A., Mossé, Yaël P.

“…Activating point mutations in Anaplastic Lymphoma Kinase (ALK ) have positioned ALK as the only mutated oncogene tractable for targeted therapy in…”
Get full text

Comprehensive pharmacological profiling of neurofibromatosis cell lines by Guo, Jianman, Grovola, Michael R, Xie, Hong, Coggins, Grace E, Duggan, Patrick, Hasan, Rukhsana, Huang, Jiale, Lin, Danny W, Song, Claire, Witek, Gabriela M, Berritt, Simon, Schultz, David C, Field, Jeffrey

“…Patients with Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2) are predisposed to tumors of the nervous system. NF1 patients predominantly…”
Get full text

Abstract 1633: Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas by Matkar, Smita, Sano, Renata, Larmour, Colleen, Krytska, Kateryna, Witek, Gabriela M., Gerelus, Mark, Stuhlmiller, Tim J., Johnson, Gary L., Mosse, Yael P.

“…The discovery of mutations in the ALK oncogene as the genetic etiology of familial neuroblastoma (NB) and as somatically acquired in 14% of patients with the…”
Get full text